Clinical Insights and Patient Considerations for Frontline TKI Therapy in Advanced uHCC
An expert discusses how treatment selection for first-line (1L) tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC) requires careful evaluation of multiple factors, including liver function (Child-Pugh status), ECOG performance status, tumor burden, and presence of macrovascular invasion or extrahepatic spread. In reviewing individual cases, clinicians assess liver enzyme levels, α-fetoprotein values, radiographic findings, and comorbidities.
Video content above is prompted by the following:
- From your clinical experience, how do you determine which patients are best suited for 1L systemic TKI therapy for advanced unresectable HCC (uHCC)?
- What factors/details from the patient case (history/diagnostics) are notable?
- What factors do you consider most when making treatment decisions, and how do those factors influence your treatment approach?
- How do you determine which patients would benefit from lenvatinib or sorafenib?
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
